Hudson Bay Capital Management
TRVI icon

Hudson Bay Capital Management’s Trevi Therapeutics TRVI Stock Holding History

Hudson Bay Capital Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,770
Closed -$140K – 1700
2026
Q1 		$140K Sell
11,770
-63,230
-84% -$708K ﹤0.01% 1149
2025
Q4 		$939K Buy
+75,000
New +$867K ﹤0.01% 804
2025
Q1 		– Sell
-100,000
Closed -$412K – 1468
2024
Q4 		$412K Buy
100,000
+50,000
+100% +$160K ﹤0.01% 815
2024
Q3 		$167K Buy
+50,000
New +$149K ﹤0.01% 754

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Hudson Bay Capital Management's TRVI Position: Q2 2026 in Review

Hudson Bay Capital Management sold out of Trevi Therapeutics (TRVI) in Q2 2026, closing a stake of 11,770 shares — an estimated $140K sold.

Hudson Bay Capital Management first reported a position in TRVI in Q3 2024 and held it in 4 quarters. The position peaked at $939K in Q4 2025. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Hudson Bay Capital Management reported no remaining Trevi Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 11,770 Trevi Therapeutics shares in Q2 2026, an estimated $140K.
  • Hudson Bay Capital Management first reported a position in Trevi Therapeutics in Q3 2024 and held it in 4 quarters.
  • Hudson Bay Capital Management's Trevi Therapeutics position peaked at $939K in Q4 2025.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.